Article Per Year (5 Year)
p-Index From 2020 - 2025
0
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cardiology Journal of Global Pharma Technology
Dadang Hendrawan
Unknown Affiliation
Health Professions Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Improvement of level MDA and SOD Using of Ganoderma Lucidum as Adjunctive Treatment for Statin Based Therapy in High Risk Patient Based on Framingham Score vitriyaturrida vitriyaturrida; M Saifur Rohman; Djanggan Sargowo; Dadang Hendrawan
Jurnal Kardiologi Indonesia Vol 39 No 3 (2018): Indonesian Journal of Cardiology: July-September 2018
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.v39i3.820

Abstract

It is well known from previous research on the importance of antioxidants to inhibit the progression of coronary heart disease in high-risk patients based on framingham scores. Statins are routinely administered in high-risk patients based on the Dyslipidemia 2016 ESC guidelines but the effects of adding Ganoderma are known to have antioxidant effects, in patients who have received statins. This study aims to assess the effect of antioxidants through measurement of SOD and MDA in patients given a combination of Ganoderma lucidum with statins.Method: A total of 24 patients with high-risk patients based on the Framingham score > 20% were selected as sample of study. Patients with respondents who had never received statin therapy or ACEi or ARB or CCB or beta blocker, or did not routinely consume the drug for 2 weeks were excluded from this study. The addition of Ganoderma lucidum dose of 3x250 mg was added to statins as the first group and Ganoderma lucidum dose of 3x250 mg was added to the Statin combination of Angiotensin Converting Enzym inhibitors (ACE inhibitors) or Angiotensin Receptor Blockers (ARB) and or Calcium Channel Blockers (CCB) and or Beta blockers as second group for 90 days. SOD and MDA levels were measured before and after the administration of Ganoderma Lucidum with the ELISA method.Result: After the administration of Ganoderma Lucidum with standard therapy, there was a decrease in MDA levels and an increase in SOD levels after 90 days in two groups. Conclusion: The addition of Ganoderma Lucidum to standard therapy can reduce oxidant levels in high-risk patients based on framingham scores. Keyword: Superoxyde-dismutase, Malondyaldehide, Oxidative Stress, Antioxidant, Ganoderma Lucidum, Statin
Lipoprotein-Associated Phospholipase A2 Activity increase the Sensitivity of Framingham Score for detecting the incidence of Acute Myocardial Infarction in sub-population of Indonesian Male Patients Andi Wahjono; Saifur Rohman; Miryanti Cahyaningtias; Rina Yudha; Yanna Indrayana; Mifetika lukitasari; Rusdianto Rusdianto; Aditya Kurniawan; Djanggan Sargowo; Sasmojo Widito; Dadang Hendrawan; Jayarani Fatimah Putri; widodo Ph.D
Journal of Global Pharma Technology Vol. 9 Issue 7 : 2017
Publisher : Journal of Global Pharma Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker of cardiovascular disease. Framingham score is currently a widely used risk stratification tool for detecting the incidence of acute myocardial infarction (AMI), although it is not very sensitive. Adding Lp-PLA2 to the Framingham score can raise the odds ratio (OR) for AMI, but requires further research.Objectives: In this study, we examine the role of Lp-PLA2 in increasing the sensitivity of the Framingham score for detecting the incidence of AMI.Methods: This study was a case-control study of 97 male patients, 60 of whom had AMI and were treated in the intensive care unit as test subjects, and 37 of whom were non-AMI patients with normal treadmill test used as controls.Results:Lp-PLA2 activity was found to be higher in the AMI group than that in the control group (83.97 ± 27.15 nmol/ml/min vs. 55.04 ± 31.99 nmol/ml/min). Eighteen patients (30%) with AMI were included in the high-risk category according to the Framingham score; this number increased to 36 patients after the addition of Lp-PLA2 activity to the Framingham score. Analysis using a receiver operating characteristic (ROC) showed a cut-off value for Lp-PLA2 activity associated with AMI of approximately 74.21 nmol/ml/min with an accuracy of 67%. The OR for detecting AMI incidence increased after the addition of Lp-PLA2 activity from 1:01 (CI 95%, 0.414–2.48) to 4.67 (CI 95%, 1.88-11.61).Conclusions:   The addition of Lp-PLA2 activity may increase the sensitivity of the Framingham score for detecting the incidence of AMI.
Co-Authors ADITYA KURNIAWAN Andi Wahjono Djanggan Sargowo Jayarani Fatimah Putri M Saifur Rohman Mifetika Lukitasari Miryanti Cahyaningtias Rina Yudha Rusdianto Rusdianto Saifur Rohman Sasmojo Widito vitriyaturrida vitriyaturrida widodo Ph.D yanna indrayana